FDA approves Perjeta for neoadjuvant breast cancer treatment
The U.S. Food and Drug Administration granted accelerated approval to Perjeta as part of a complete treatment regimen for patients with early stage breast cancer before surgery. Perjeta is the first FDA-approved drug for the neoadjuvant treatment of breast cancer. Perjeta was approved in 2012 for the treatment of patients with advanced or late-stage HER2-positive breast cancer.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063